nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.04.2012 | Original Article

Comparison of ¹⁸F-DOPA, ¹⁸F-FDG and ⁶⁸Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma

verfasst von: Giorgio Treglia, Paola Castaldi, Maria Felicia Villani, Germano Perotti, Chiara de Waure, Angelina Filice, Valentina Ambrosini, Nadia Cremonini, Monica Santimaria, Annibale Versari, Stefano Fanti, Alessandro Giordano, Vittoria Rufini

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To retrospectively evaluate and compare ¹⁸F-FDG, ¹⁸F-DOPA and ⁶⁸Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels.

Methods

Included in the study were 18 patients with recurrent MTC in whom functional imaging with the three tracers was performed. The PET/CT results were compared on a per-patient basis and on a per-lesion-basis.

Results

At least one focus of abnormal uptake was observed on PET/CT in 13 patients with ¹⁸F-DOPA (72.2% sensitivity), in 6 patients with ⁶⁸Ga-somatostatin analogues (33.3%) and in 3 patients with ¹⁸F-FDG (16.7%) (p < 0.01). There was a statistically significant difference in sensitivity between ¹⁸F-DOPA and ¹⁸F-FDG PET/CT (p < 0.01) and between ¹⁸F-DOPA and ⁶⁸Ga-somatostatin analogue PET/CT (p = 0.04). Overall, 72 lesions were identified on PET/CT with the three tracers. ¹⁸F-DOPA PET/CT detected 85% of lesions (61 of 72), ⁶⁸Ga-somatostatin analogue PET/CT 20% (14 of 72) and ¹⁸F-FDG PET/CT 28% (20 of 72). There was a statistically significant difference in the number of lymph node, liver and bone lesions detected with the three tracers (p < 0.01). In particular, post-hoc tests showed a significant difference in the number of lymph node, liver and bone lesions detected by ¹⁸F-DOPA PET/CT and ¹⁸F-FDG PET/CT (p < 0.01 for all the analyses) and by ¹⁸F-DOPA PET/CT and ⁶⁸Ga-somatostatin analogue PET/CT (p < 0.01 for all the analyses). The PET/CT results led to a change in management of eight patients (44%).

Conclusion

¹⁸F-DOPA PET/CT seems to be the most useful imaging method for detecting recurrent MTC lesions in patients with elevated serum calcitonin levels, performing better than ¹⁸F-FDG and ⁶⁸Ga-somatostatin analogue PET/CT. ¹⁸F-FDG may complement ¹⁸F-DOPA in patients with an aggressive tumour.

Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol. 2010;22:475–85.CrossRef

Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–48.PubMedCrossRef

Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer. 2003;88:1537–42.PubMedCrossRef

American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells Jr SA. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612.PubMedCrossRef

Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22–32.PubMedCrossRef

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumours. Semin Nucl Med. 2006;36:228–47.PubMedCrossRef

Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D. Role of PET in medullary thyroid carcinoma. Minerva Endocrinol. 2008;33:67–73.PubMed

Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Körber C, Grünwald F. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med. 2001;28:1671–6.PubMedCrossRef

de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004;11:786–94.PubMedCrossRef

10.

Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71.PubMedCrossRef

11.

Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1604–9.PubMedCrossRef

12.

Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524–31.PubMedCrossRef

13.

Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfürst S, Pirich C, Dralle H, Langsteger W. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19:1425–34.PubMedCrossRef

14.

Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, Fanti S, Gross MD, Al-Nahhas A, Rubello D. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414–21.PubMedCrossRef

15.

Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, Bomanji JB. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49–57.PubMedCrossRef

16.

Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984;199:461–6.PubMedCrossRef

17.

Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, Pettinato V, Malizia C, Lodi F, Fanti S. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52:886–90.PubMedCrossRef

18.

Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, Gallo C, Giunta FP, Fraternali A, Salvo D, Asti M, Azzolini F, Iori V, Sassatelli R. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med. 2010;35:321–8.PubMedCrossRef

19.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527–33.PubMedCrossRef

20.

Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelmans L, Reske SN. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:BP115–24.PubMed

21.

Faggiano A, Grimaldi F, Pezzullo L, Chiofalo MG, Caracò C, Mozzillo N, Angeletti G, Santeusanio F, Lombardi G, Colao A, Avenia N, Ferolla P. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. Endocr Relat Cancer. 2009;16:225–31.PubMedCrossRef

22.

Adams S, Baum RP, Hertel A, Schumm-Dräger PM, Usadel KH, Hör G. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun. 1998;19:641–7.PubMedCrossRef

23.

Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, Shaha AR, Tuttle RM, Shah JP, Larson SM. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48:501–7.PubMedCrossRef

24.

Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med. 2000;27:490–6.PubMedCrossRef

25.

Szakáll Jr S, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Agoston P, Trón L. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002;43:66–71.PubMed

26.

Gotthardt M, Battmann A, Höffken H, Schurrat T, Pollum H, Beuter D, Gratz S, Béhé M, Bauhofer A, Klose KJ, Behr TM. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun. 2004;25:439–43.PubMedCrossRef

27.

Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control. 2005;12:254–60.PubMed

28.

Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.PubMedCrossRef

29.

Iagaru A, Masamed R, Singer PA, Conti PS. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol. 2007;9:72–7.PubMedCrossRef

30.

Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590–7.PubMedCrossRef

31.

Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, Al-Nahhas A, Gross MD. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol. 2008;34:581–6.PubMedCrossRef

32.

Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Björo T, Hay ID, Lowe VJ. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 2010;12:547–53.PubMedCrossRef

33.

Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, Tolis G, Datseris IE. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010;31:567–75.PubMed

34.

Dörr U, Sautter-Bihl ML, Bihl H. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol. 1994;21(5 Suppl 13):42–5.PubMed

35.

Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996;37:912–6.PubMed

36.

Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001;54:641–9.CrossRef

37.

Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991;64:567–73.PubMed

38.

Behr TM, Gratz S, Markus PM, Dunn RM, Hüfner M, Schauer A, Fischer M, Munz DL, Becker H, Becker W. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer. 1997;80(12 Suppl):2436–57.PubMedCrossRef

39.

Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:46–8.PubMedCrossRef

40.

Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, Lopera Sierra M, Cremonesi M, Chinol M, Mäcke HR, Paganelli G. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm. 2004;19:65–71.PubMedCrossRef

Titel: Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
verfasst von: Giorgio Treglia
Paola Castaldi
Maria Felicia Villani
Germano Perotti
Chiara de Waure
Angelina Filice
Valentina Ambrosini
Nadia Cremonini
Monica Santimaria
Annibale Versari
Stefano Fanti
Alessandro Giordano
Vittoria Rufini
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-2031-6

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2

Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer

Assessing global cardiovascular molecular calcification with 18F-fluoride PET/CT: will this become a clinical reality and a challenge to CT calcification scoring?

Demonstration of peripheral nerve root involvement by non-Hodgkin’s lymphoma on 18F-FDG PET/CT

Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up

EANM Marie Curie Training Project Report 2011 University Hospital of Santiago de Compostela, Nuclear Medicine Department: Dr. Patricia Arce